A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

• Status: Withdrawn
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.

• Phase: Phase 3

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Outpatients

• Must sign informed consent prior to protocol-related procedures

Exclusion Criteria:

• Women who are pregnant, trying to become pregnant, or nursing

• Significant risk of committing suicide

• Any serious unstable medical conditions